0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD38

CD38

CD38 Molecule Information

Name:Lymphocyte differentiation antigen CD38
Target Synonym:2 -phospho-ADP-ribosyl cyclase;T10;CD38;2 -phospho-cyclic-ADP-ribose transferase;CD_antigen=CD38;2 -phospho-ADP-ribosyl cyclase/2 -phospho-cyclic-ADP-ribose transferase;ADPRC 1;Cyclic ADP-ribose hydrolase 1;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

CD38 Protein Product ListCompare or Buy

CD38 Molecule Synonym Name

CD38,T10,cADPr hydrolase 1

CD38 Molecule Background

CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.

CD38 References

CD38 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Daratumumab JNJ-54767414 Approved Janssen DARZALEX fda Multiple myeloma (MM) JANSSEN BIOTECH 2015-11-16 Multiple myeloma (MM) Details

CD38 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GBR-1342 GBR-1342 Phase Ⅰ Glenmark Pharmaceuticals Multiple myeloma (MM) Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase Ⅰ Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple myeloma (MM) Details
TAK-079 TAK-079 Phase Ⅱ Takeda Multiple myeloma (MM) Details
AMG-424 AMG-424 Phase Ⅰ Xencor, Amgen Multiple myeloma (MM) Details
Isatuximab SAR-650984 BLA Filing ImmunoGen, Sanofi Multiple myeloma (MM) Details
TAK-573 TAK-573; TEV-48573 Phase Ⅱ Takeda Multiple myeloma (MM) Details
TAK-169 TAK-169 IND Filing Molecular Templates, Takeda Multiple myeloma (MM) Details
FT-500 FT-500; FT-516; FT-538; FT-596 Phase Ⅰ Fate therapeutics, University of Minnesota Solid tumours Details
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) Phase Ⅰ Sorrento Therapeutics, Celularity Multiple myeloma (MM) Details
MOR-202 MOR-202; MOR-03087; TJ-202 Phase Ⅲ MorphoSys, I-MAB Biopharma Multiple myeloma (MM) Details

This web search service is supported by Google Inc.

totop